| Market Cap | 149.66M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -98.59M | Forward P/E | -4.00 | EPS next Y | - | 50D Avg Chg | -19.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -44.00% |
| Dividend | N/A | Price/Book | 95.65 | EPS next 5Y | - | 52W High Chg | -83.00% |
| Recommedations | 2.00 | Quick Ratio | 0.00 | Shares Outstanding | 34.65M | 52W Low Chg | 44.00% |
| Insider Own | 71.99% | ROA | -681.99% | Shares Float | 3.72M | Beta | 1.30 |
| Inst Own | 13.53% | ROE | - | Shares Shorted/Prior | 643.94K/873.36K | Price | 4.40 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,886,903 | Target Price | 18.50 |
| Oper. Margin | - | Earnings Date | - | Volume | 424,350 | Change | -5.58% |
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.
| Taglich Brothers | Speculative Buy | May 31, 23 |
| EF Hutton | Buy | Apr 27, 23 |
| EF Hutton | Buy | Apr 13, 23 |
| Fundamental Research Corp. | Buy | Mar 16, 23 |
| EF Hutton | Buy | Mar 13, 23 |